Anti-HER2 antibodies
Antibodies, antigen-binding fragments and polypeptides that bind to HER2 are disclosed, as well as nucleic acids and vectors encoding the same. Also provided are cells comprising the antibodies, antigen-binding fragments, polypeptides, nucleic acids and vectors, methods of making such molecules, and the use of such molecules for therapeutic applications.
1. An antibody or antigen binding fragment thereof which is capable of binding to HER2, optionally isolated, wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region incorporating the following CDRs:
(SEQ ID NO: 255)
LC-CDR1: GLSSGSVSTTYYPS
(SEQ ID NO: 33)
LC-CDR2: STNTRSS
(SEQ ID NO: 256)
LC-CDR3: VLYMGNGISV;
a heavy chain variable region incorporating the following CDRs:
(SEQ ID NO: 24)
HC-CDR1: SSSYYWG
(SEQ ID NO: 25)
HC-CDR2: SIYYSGSTYYNPSLKS
(SEQ ID NO: 26)
HC-CDR3: YAPDSSGYLVAFDI.
2. The antibody, or antigen binding fragment thereof, according to claim 1 conjugated to a drug moiety or a detectable moiety.
3. The antibody, or antigen binding fragment thereof according to claim 2 wherein the drug moiety comprises an anti-cancer drug moiety.
4. A nucleic acid, optionally isolated, encoding an antibody, or antigen binding fragment thereof which is capable of binding to HER2, wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region incorporating the following CDRs:
LC-CDR1:
(SEQ ID NO: 255)
GLSSGSVSTTYYPS
LC-CDR2:
(SEQ ID NO: 33)
STNTRSS
LC-CDR3:
(SEQ ID NO: 256)
VLYIVIGNGISV;
and
a heavy chain variable region incorporating the following CDRs:
(SEQ ID NO: 24)
HC-CDR1: SSSYYWG
(SEQ ID NO: 25)
HC-CDR2: SIYYSGSTYYNPSLKS
(SEQ ID NO: 26)
HC-CDR3: YAPDSSGYLVAFDI.
5. A method of treating cancer, the method comprising administering an antibody, or antigen binding fragment thereof, to a patient suffering from cancer,
wherein the antibody or antigen binding fragment thereof is capable of binding to HER2, and comprises:
a light chain variable region incorporating the following CDRs:
LC-CDR1:
(SEQ ID NO: 255)
GLSSGSVSTTYYPS
LC-CDR2:
(SEQ ID NO: 33)
STNTRSS
LC-CDR3:
(SEQ ID NO: 256)
VLYMGNGISV;
and
a heavy chain variable region incorporating the following CDRs:
HC-CDR1:
(SEQ ID NO: 24)
SSSYYWG
HC-CDR2:
(SEQ ID NO: 25)
SIYYSGSTYYNPSLKS
HC-CDR3:
(SEQ ID NO: 26)
YAPDSSGYLVAFDI.
6. The method according to claim 5 , wherein the cancer is a HER2-positive cancer.
7. The method according to claim 5 , wherein the cancer comprises a HER2-positive tumour cell.
8. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region having at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:253; and
a heavy chain variable region having at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:254.
9. The antibody or antigen binding fragment thereof according to claim 1 , wherein the antibody or antigen binding fragment thereof binds specifically to human, rhesus macaque or murine HER2.
10. The nucleic acid according to claim 4 , wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region having at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:253; and
a heavy chain variable region having at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:254.
11. The nucleic acid according to claim 4 , wherein the antibody or antigen binding fragment thereof binds specifically to human, rhesus macaque or murine HER2.
12. The nucleic acid according to claim 4 , wherein the antibody or antigen binding fragment thereof is conjugated to a drug moiety or a detectable moiety.
13. The nucleic acid according to claim 12 , wherein the drug moiety comprises an anti-cancer drug moiety.
14. The method according to claim 5 , wherein the antibody or antigen binding fragment thereof comprises:
a light chain variable region having at least 85% sequence identity to the light chain variable region sequence of SEQ ID NO:253; and
a heavy chain variable region having at least 85% sequence identity to the heavy chain variable region sequence of SEQ ID NO:254.
15. The method according to claim 5 , wherein the antibody or antigen binding fragment thereof binds specifically to human, rhesus macaque or murine HER2.
16. The method according to claim 5 , wherein the antibody or antigen binding thereof fragment is conjugated to a drug moiety or a detectable moiety.
17. The method according to claim 16 , wherein the drug moiety comprises an anti-cancer drug moiety.